This Article Full Text Full Text (PDF) All Versions of this Article: 25/4/821    most recent 01.ATV.0000157784.25920.a7v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, M.-P. Articles by Lee, Y.-J. Search for Related Content PubMed PubMed Citation Articles by Chen, M.-P. Articles by Lee, Y.-J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:821.)
© 2005 American Heart Association, Inc.

Atherosclerosis & Lipoproteins

Hypoadiponectinemia Is Associated With Ischemic Cerebrovascular Disease

Miao-Pei Chen; Jack C.-R. Tsai; Fu-Mei Chung; Sheng-Shan Yang; Liang-Lan Hsing; Shyi-Jang Shin; Yau-Jiunn Lee

From the Departments of Clinical Research (M.-P.C., J.C.-R.T., F.-M.C., Y.-J.L.), Neurology (S.-S.Y.), and Clinical Laboratory (L.-L.H.), Pingtung Christian Hospital, Taiwan; and the Graduate Institute of Medicine (S.-J.S.), Kaohsiung Medical University, Taiwan.

Correspondence to Dr Yau-Jiunn Lee, Department of Clinical Research, Pingtung Christian Hospital, No.60 Da-Lien Rd, Pingtung, 90000, Taiwan. E-mail t3275{at}ms25.hinet.net

Objective— Adiponectin, an adipocyte-derived peptide with antiinflammatory and antiatherogenic effects, is known to protect against the initiation and progression of atherosclerosis. In this study, we investigate whether hypoadiponectinemia is present in patients with ischemic cerebrovascular disease (CVD).

Methods and Results— In this case-control study, plasma adiponectin concentration was measured by an enzyme-linked immunosorbent assay in type 2 diabetic and nondiabetic subjects with or without ischemic CVD. A total of 534 subjects were studied. The mean plasma level of adiponectin of the 228 patients with ischemic CVD was significantly lower than that of 306 subjects without CVD. When the analysis was stratified according to diabetes status, plasma levels of adiponectin in CVD subjects with or without type 2 diabetes were significantly lower than those of their counterparts. Decreasing concentrations of adiponectin were independently and significantly associated with a higher risk of CVD when concentrations were analyzed by quartile and as a continuous variable. When patients with CVD were subgrouped according to the comorbidity with or without type2 diabetes, the same trend of association between plasma adiponectin and risk of CVD was observed in each group.

Conclusion— These data show that there are significantly lower levels of plasma adiponectin in patients with ischemic CVD.

Adiponectin, an adipocyte-derived peptide with antiinflammatory and antiatherogenic effects, is known to protect against the initiation and progression of atherosclerosis. In this study, we investigate whether hypoadiponectinemia is present in patients with ischemic cerebrovascular disease (CVD). Our data show that there are significantly lower levels of plasma adiponectin in patients with ischemic CVD.

Key Words: adiponectin • atherosclerosis • cerebrovascular disease • metabolic syndrome • type 2 diabetes mellitus

This article has been cited by other articles:

				M. S. Denzel, L. W. Hebbard, G. Shostak, L. Shapiro, R. D. Cardiff, and B. Ranscht Adiponectin Deficiency Limits Tumor Vascularization in the MMTV-PyV-mT Mouse Model of Mammary Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3256 - 3264. [Abstract] [Full Text] [PDF]

				G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., December 2, 2008; 29(24): 2959 - 2971. [Abstract] [Full Text] [PDF]

				M. Matsumoto, S. Ishikawa, and E. Kajii Association of Adiponectin With Cerebrovascular Disease: A Nested Case-Control Study Stroke, February 1, 2008; 39(2): 323 - 328. [Abstract] [Full Text] [PDF]

				M. Nishimura, Y. Izumiya, A. Higuchi, R. Shibata, J. Qiu, C. Kudo, H. K. Shin, M. A. Moskowitz, and N. Ouchi Adiponectin Prevents Cerebral Ischemic Injury Through Endothelial Nitric Oxide Synthase-Dependent Mechanisms Circulation, January 15, 2008; 117(2): 216 - 223. [Abstract] [Full Text] [PDF]

				O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee Adiponectin levels in patients with intracranial atherosclerosis Neurology, May 29, 2007; 68(22): 1931 - 1937. [Abstract] [Full Text] [PDF]

				P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]

				S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]

				H. H. Hegener, I-M. Lee, N. R. Cook, P. M. Ridker, and R. Y.L. Zee Association of Adiponectin Gene Variations with Risk of Incident Myocardial Infarction and Ischemic Stroke: A Nested Case-Control Study Clin. Chem., November 1, 2006; 52(11): 2021 - 2027. [Abstract] [Full Text] [PDF]

				W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, and H. Lowel Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men: Results From the 18-Year Follow-Up of a Large Cohort From Southern Germany J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1369 - 1377. [Abstract] [Full Text] [PDF]

				M.-P. Chen, F.-M. Chung, D.-M. Chang, J. C.-R. Tsai, H.-F. Huang, S.-J. Shin, and Y.-J. Lee Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 295 - 299. [Abstract] [Full Text] [PDF]